tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Palvella Therapeutics price target raised to $66 from $52 at Canaccord

Canaccord raised the firm’s price target on Palvella Therapeutics (PVLA) to $66 from $52 and keeps a Buy rating on the shares. The firm said its 2Q25 earnings report was incremental following enrollment completion of its phase 3 SELVA trial for mLM, which exceeded its target (n=40) by over 25% (n=51). Top-line results are on track for 1Q26.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1